TORONTO, Oct. 22, 2025 /CNW/ - Health Canada has approved Dupixent® (dupilumab injection) as an add-on maintenance treatment in adult patients with chronic obstructive pulmonary disease (COPD) ...
Approval in moderate-to-severe patients was based on pivotal trial results showing over four times more Dupixent patients experienced sustained ...
Sanofi and Regeneron’s Dupixent approved in Japan as the first targeted medicine to treat adults with bullous pemphigoidApproval in ...
Please provide your email address to receive an email when new articles are posted on . IL-13, which dupilumab blocks, induces nitric oxide production, which leads to mucus hypersecretion. At week 24, ...
In phase 3 trials, dupilumab significantly reduced itch and hives compared with placebo. The Food and Drug Administration (FDA) has approved Dupixent ® (dupilumab) for the treatment of adult and ...
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Approximately half of patients do not respond to H1 ...
BOSTON -- Add-on dupilumab (Dupixent) significantly reduced itching and urticaria in patients with chronic spontaneous urticaria (CSU) whose symptoms were uncontrolled with H1-antihistamine therapy.
Sanofi & Regeneron’s Dupixent receives Japanese marketing approval to treat adults with moderate-to-severe bullous pemphigoid: Paris Wednesday, March 25, 2026, 09:00 Hrs [IST] T ...
Bhatt’s study, "Dupilumab for COPD with Type 2 Inflammation Indicated by Eosinophil Counts,” was recently published in The New England Journal of Medicine. Bhatt and colleagues conducted a multicenter ...
The FDA approved dupilumab (Dupixent) for chronic spontaneous urticaria (CSU) in patients 12 years and older, the first new targeted drug for the inflammatory skin disease in over a decade, drugmakers ...
Approval covers adults and children ≥6 years with prior sinonasal surgery, representing the first FDA-cleared pharmacologic option specifically for AFRS and dupilumab’s ninth U.S. indication.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results